This guideline addresses the clinical development requirements of fixed combination medicinal products, which shall reflect their intended therapeutic use and indication. It replaces the guideline on clinical development of fixed combination medicinal products – CHMP/EWP/240/95 Rev. 1.

 

 

Posted on the EMA website on 13 May 2015